DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Natco Pharma Limited — Investor Presentation

NSE 53 min ago·19 Aug 2026, 3:32 am

Natco Pharma

Natco Pharma Limited has announced the release of its investor presentation to the stock exchanges. This document is typically used to communicate the company's strategic roadmap, future growth plans, and performance metrics to shareholders and the market.

For investors, this update offers a crucial opportunity to understand the management's vision for the company's future. It provides transparency on how Natco plans to navigate the competitive pharmaceutical landscape and execute its business strategy.

Investors should pay close attention to the details regarding the company's product pipeline, upcoming launches, and financial outlook presented in the slides. This information is key to assessing the company's long-term growth potential.